ArticleCancer medicine2026
Efficacy and Safety of Low-Frequency Daratumumab Regimen in Systemic Light-Chain Amyloidosis.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
In recent years, daratumumab has been increasingly applied in the treatment of systemic light-chain (AL) amyloidosis, significantly improving the prognosis of patients. Currently, the internationally recognized daratumumab treatment regimen comes from the ANDROMEDA trial. Given the low tumor burden and poor tolerance of patients with amyloidosis, in this study, we modified the ANDROMEDA-based protocol by administering daratumumab at half the original frequency. We enrolled 48 patients with AL amyloidosis who received low-frequency daratumumab in multiple hospitals from July 2021 to May 2024 (ChiCTR2100049253). Among these patients, 38 were newly diagnosed and 10 were relapsed and refractory patients. At 3 months, the percentage of newly diagnosed patients with hematologic response≥very good partial response (VGPR) was 75.8%, including 36.4% complete response (CR) and 39.4% VGPR, with an overall response rate (ORR) of 90.9%. The CR, VGPR and ORR rates of relapsed and refractory patients at 3 months were 40.0%, 20.0% and 90.0%, respectively. By 6 months, ≥VGPR was achieved by 86.7% of newly diagnosed patients, while CR, VGPR, and ORR in relapsed and refractory patients were 44.4%, 22.2%, and 77.8%. The 6-month cardiac and renal response rates were 61.9% and 46.2% in newly diagnosed patients, 20.0% and 50.0% in relapsed and refractory patients, respectively. The median follow-up time was 26.0 months. The 1-year and 2-year OS rates were both 89.5% for newly diagnosed patients, and 90.0% for relapsed and refractory patients. Of the 48 patients, 33 (68.8%) received maintenance therapy and 15 (31.3%) did not. The 1-year and 2-year OS rates were both 100.0% for patients receiving maintenance, and 66.7% for patients without maintenance. Considering the safety endpoints, 86.8% of newly diagnosed patients experienced at least one adverse event (AE). In conclusion, the low-frequency daratumumab regimen can be considered as an effective, safe and feasible treatment strategy for AL amyloidosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.